Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049829
Status:
COMPLETED
Last Update Posted:
2011-11-02
First Post:
2002-11-14
Brief Title:
HORIZON-PFT Pivotal Fracture Trial
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
HORIZON-PFT Pivotal Fracture Trial
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HORIZON-PFT Pivotal Fracture Trial will study the effect of zoledronic acid given once per year on the treatment of osteoporosis in women past menopause Hip and vertebral fractures are the most devastating consequences of osteoporosis HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None